In a noteworthy update for investors, Theriva Biologics, Inc. (TOVX) has received a Buy rating from Jason McCarthy of Maxim Group as of March 31, 2026. This recommendation comes at a time when the stock is priced at $0.1958, with a significant upside potential towards the analyst’s price target of $1. This rating could serve as a catalyst for investor interest, suggesting that the company may have the potential to rebound from its recent struggles.
Recent Price Action
Theriva’s stock has experienced a tumultuous period, currently trading at $0.1958, down sharply from its 52-week high of $21.01, representing a staggering 86.87% decline. On the other end of the spectrum, the year’s low was strikingly close at just $0.1958, indicating the challenging environment the company has faced. Recently, the stock saw a slight upturn, with a change of $0.0106 or an increase of 5.72%. Despite this uptick, trading volumes have been relatively low, with recent sessions witnessing a volume of 1,980,521 shares compared to an average volume of 12,499,141. The market cap stands at $6,987,779. With a beta of 0.515, the stock shows less volatility compared to the broader market, suggesting that while it is prone to sharp movements, it doesn’t exhibit the extreme volatility of higher-beta stocks.
Historical Performance
Over the past month, TOVX has faced tough headwinds, recording a 30-day performance of -1.31%. This aligns with a more challenging quarterly performance of -57.02%, reflecting broader market dynamics and possibly company-specific struggles. The yearly performance is strikingly negative, showcasing an -87.34% return. These figures indicate significant pressures that continue to impact investor sentiment. Despite some trading stability, the stock has demonstrated volatility, with a weekly volatility of 7.98% and a monthly volatility of 11.66%. Average trading volumes in the last 10 days have surged to 48,938,682, further suggesting fluctuations in investor interest.
Earnings Analysis
In its latest earnings report, Theriva reported an actual EPS of -$0.45068, which fell short of the estimated EPS of -$0.38, resulting in an 18.6% EPS surprise to the downside. This contrasts with the previous earnings report, where the company significantly missed expectations with an EPS of -$1.93 compared to an estimate of -$0.38, reflecting a staggering variance of 407.89%. These results highlight the challenges the company faces in terms of earnings predictability and quality, complicating the investment narrative and contributing to its depressed stock price.
Analyst / Consensus View
The consensus view surrounding TOVX appears cautiously optimistic, with a recent Buy rating from Jason McCarthy of Maxim Group. Currently, the stock maintains an aggregate rating of 1, with all ratings categorized as Buy and none as Hold or Sell. The average price target also aligns closely with McCarthy’s target at $1, indicating a strong consensus among analysts regarding its undervaluation. Given the stock’s recent performance, this sentiment suggests that analysts believe the company has the potential to recover from its current lows.
Stock Grading or Fundamental View
Theriva Biologics has received a Stocks Telegraph Grade of 31. This score, which aggregates various financial and market analysis indicators, suggests rather weak fundamentals at this time. The low grading signals that the company may be contending with structural issues or is undergoing necessary transformations that have yet to take hold. For potential investors, the current score indicates caution, reflecting the necessity for improvement before assuming considerable risk.
Conclusion
For investors contemplating a position in Theriva Biologics, the stock may appeal more to those with a high-risk tolerance seeking long-term growth opportunities. The recent Buy recommendation from Maxim Group highlights potential upside; however, substantial risks persist due to its volatile past performance and uncertain earnings outlook. As the stock trades at an extreme discount to its former valuations, monitoring developments within the company will be vital. Investors should watch closely for signs of recovery, but they must also remain aware of the significant obstacles ahead.